PTSM: Pharmaceutical Technology Sourcing and Management, May 4, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, May 4, 2011
APIs
Growth in the US Prescription Drug Market Slows
By Patricia Van Arnum
Volume growth in the US prescription drug market was at historically low levels in 2010, and revenue growth was anemic.
Outsourcing
A Hard Look at Third-Party External Supply Networks
By Gregg Brandyberry
The complexity of third-party external supply networks requires new ways to manage them.
Pharma Partner Focus
Spectrum Chemical Expands in China
By Patricia Van Arnum
Spectrum Chemical Mfg., a supplier of bulk fine chemicals and pharmaceutical ingredients, opens new facilities in China and augments its custom-synthesis business.
Sourcing
Innovation in the Pharma Supply Chain
By Patricia Van Arnum
An upcoming conference by the Drug, Chemical and Associated Technologies Association (DCAT) will focus on innovative practices and strategies for optimizing sourcing, procurement, and the management of the pharmaceutical supply chain.
CSR and Sustainability Forum
Distribution and Administration in Public Health, Government, and Developing World Markets
By Chan Harjivan , James Guyton
This article, which focuses on distribution and administration, is Part III of a three-part series on biopharmaceutical issues in public health, government, and developing-world markets.
GlaxoSmithKline and Singapore Partner in Green Manufacturing
By Patricia Van Arnum
GlaxoSmithKline and the Singapore Economic Development Board team in advancing sustainable pharmaceutical manufacturing.
CSR and Sustainability in the News
A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
11%
All of the above.
39%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here